You are here

SLAS DISCOVERY: Advancing the Science of Drug Discovery

SLAS DISCOVERY: Advancing the Science of Drug Discovery

Advancing Life Sciences R&D

eISSN: 24725560 | ISSN: 24725552 | Current volume: 26 | Current issue: 8 Frequency: 10 Times/Year
Advancing the Science of Drug Discovery: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.

SLAS Discovery is a peer-reviewed journal focusing on drug discovery sciences with a strong record of scientific rigor and impact. SLAS Discovery is an official journal of SLAS.

Come Transform Research with SLAS: SLAS Discovery and SLAS Technology readers, authors, editors and reviewers are academic, commercial and government researchers, scientists and engineers who conduct research, and develop and implement new technologies. Together, these journals address the full spectrum of issues that are mission-critical to this important audience, enabling research teams to gain scientific insights; increase productivity; elevate data quality; reduce process cycle times; and enable research and development that otherwise would be impossible.

Click here for more information about SLAS Discovery’s editorial aims and scope.

SLAS Discovery is a member of the Committee on Publication Ethics (COPE).

Advancing the Science of Drug Discovery: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.

SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success.

SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies.

SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.

SLAS Discovery is a member of the Committee on Publication Ethics (COPE).

Robert M. Campbell, Ph.D. Twentyeight-seven Therapeutics, Watertown, MA
Associate Editors
Marc Bickle, Ph.D. Institute of Translational Bioengineering at Roche in Basel, Switzerland
Timothy Spicer, PhD The Scripps Research Institute, Jupiter, FL, USA
Scientific Advisors
Ricardo Macarrón, Ph.D. VP, Applied Technology, Incyte Research Institute, Wilmington, DE USA
Lorenz M. Mayr, Ph.D. Chief Technology Officer, GE Healthcare Life Sciences, Amersham, UK
Christian Parker, Ph.D. Novartis Institutes for Biomedical Research, Basel, Switzerland
Peter Simpson, Ph.D. Medicines Discovery Catapult, Cheshire, UK
D. Lansing Taylor, Ph.D. University of Pittsburgh, USA
Podcast Editor
Rob Howes, Ph.D. AstraZeneca, Gothenburg, Sweden
Editorial Board
Alberto Bresciani, M.Sc. IRBM Science Park, Rome, Italy
Evan F. Cromwell, Ph.D. Protein Fluidics, Burlingame, CA, USA
Mei Ding, Ph.D. AstraZeneca, Gothenburg, Sweden
Marc Ferrer, Ph.D. NIH Chemical Genomics Center, Rockville, MD, USA
Amanda L. Garner, PhD University of Michigan, Ann Arbor, MI
Robert A. Goodnow, Jr, Ph.D. Pharmaron, Boston, MA, USA
Charles Hart, Ph.D. Threshold Pharmaceuticals, South San Francisco, CA, USA
Geoffrey A. Holdgate AstraZeneca, UK
Rob Howes, Ph.D. AstraZeneca, Gothenburg, Sweden
Philip Iversen, MS, PhD Luther College, Decorah, IA
Franck Madoux, PhD Amgen, Thousand Oaks, CA
Martin Main, Ph.D. Medicines Discovery Catapult, Alderley Park, Cheshire, UK
Jose Julio Martin-Plaza, Ph.D. Sciengement Lab Consulting, San Agustin del Guadalix, Spain
Larry Mattheakis, Ph.D. Protagonist Therapeutics, Newark, CA, USA
Joe McGivern, Ph.D. Denali Therapeutics, South San Francisco, CA
Robert Nadon, Ph.D. McGill University, Montréal, QC, Canada
Mariafrancesca Scalise, Ph.D. University of Calabria, Cosenza, Italy
Elizabeth R. Sharlow, PhD University of Virginia, Charlottesville, VA, USA
Masoud Vedadi, Ph.D. University of Toronto, Toronto, ON, Canada
Francisca Vicente, Ph.D. Fundación MEDINA, Granada, España, Spain
Andreas Vogt, Ph.D. University of Pittsburgh Drug Discovery Institute, Department of Computational and Systems Biology, Pittsburgh, PA, USA
Publishing Manager
  • BIOSIS database
  • Biomolecular Interaction Network Database (BIND)
  • Biotechnology Citation Index®
  • Chemical Abstracts Service (CAS)
  • Clarivate Analytics: BIOSIS Previews
  • Clarivate Analytics: Current Contents - Life Sciences
  • EMBASE/Excerpta Medica
  • EMBiology
  • Elsevier BV: BIOBASE
  • Index Medicus
  • InfoTrac (full text)
  • ProQuest
  • Prous Science Integrity®
  • PubMed: MEDLINE
  • Science Citation Index Expanded (Web of Science)
  • Scopus
  • SLAS Author Instructions

    SLAS Discovery SAGE Track System (Submit a Manuscript)

    Average time from submission to first decision: 29 days.